Skip to main content
. Author manuscript; available in PMC: 2021 Dec 18.
Published in final edited form as: Mol Genet Metab. 2021 Jan 13;132(2):119–127. doi: 10.1016/j.ymgme.2021.01.001

Table 3.

Summary of drug-related adverse events.

Drug-related AEs occurring in > 10% of patients, N (%) Age group
Total (n = 65)
<1 year (n = 11) 1 to < 2 years (n = 11) 2 to < 4 years (n= 23) 4 to < 7 years (n = 20)

Upper respiratory tract infection 3 (27.3%) 2 (18.2%) 3 (13.0%) 4 (20.0%) 12 (18.5%)
Abdominal pain 2 (18.2%) 0 6 (26.1%) 2 (10.0%) 10 (15.4%)
Vomiting 2 (18.2%) 3 (27.3%) 4 (17.4%) 1 (5.0%) 10 (15.4%)
Diarrhea 1 (9.1%) 1 (9.1%) 4 (17.4%) 2 (10.0%) 8 (12.3%)

Drug-related SAEs, N (%) Age group
Total (n = 65)
<1 year (n = 11) 1 to < 2 years(n= 11) 2 to < 4 years (n = 23) 4 to < 7 years (n = 20)

Colitis ulcerative 0 0 0 1 (5.0%) 1 (1.5%)
Diarrhea 0 0 0 1 (5.0%) 1 (1.5%)
Convulsion 0 0 1 (4.3%) 0 1 (1.5%)

AE: adverse event; N: number of patients; SAE: serious adverse events.